Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
HEC syndrome is characterized by communicating hydrocephalus, endocardial fibroelastosis (EFE), and congenital cataracts. It has been described in two children, both of whom died a few months after birth (the first as a result of a respiratory infection and the second due to cardiac complications). The etiology of the syndrome is unknown but a viral or genetic origin has been proposed.
Features include: Polyhydramnios, Endocardial fibroelastosis, Developmental cataract, and Communicating hydrocephalus.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 1 | Endocardial fibroelastosis |
Eyes |
Biomarker and diagnostic research for HEC syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for HEC syndrome.
134 publications have been identified in PubMed for HEC syndrome. Kisho has analyzed 107 by research type. Research spans Review / Meta-Analysis (52%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 56 | 52% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:30 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about HEC syndrome
1
Developmental cataract |
Brain and nerves | 1 | Communicating hydrocephalus |
Laboratory research
25 |
23% |
Disease patterns and progression | 12 | 11% |
Clinical study results | 5 | 5% |
Testing and diagnosis research | 3 | 3% |
Other research | 2 | 2% |
Patient case studies | 2 | 2% |
New treatment approaches | 2 | 2% |
Li H (2026). [PMID: 41365194](https://pubmed.ncbi.nlm.nih.gov/41365194/). *Phytomedicine*. [Basic Science / Preclinical]
Rangraze IR (2026). [PMID: 42029986](https://pubmed.ncbi.nlm.nih.gov/42029986/). *Diabetes Ther*. [Epidemiology / Natural History]
Lovette BC (2026). [PMID: 40853262](https://pubmed.ncbi.nlm.nih.gov/40853262/). *J Head Trauma Rehabil*. [Clinical Trial Publication]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Takacs P (2026). [PMID: 41805135](https://pubmed.ncbi.nlm.nih.gov/41805135/). *Menopause*. [Basic Science / Preclinical]
Ullah S (2026). [PMID: 40108106](https://pubmed.ncbi.nlm.nih.gov/40108106/). *Biochem Genet*. [Basic Science / Preclinical]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Spanoghe M (2026). [PMID: 42063762](https://pubmed.ncbi.nlm.nih.gov/42063762/). *Front Med (Lausanne)*. [Other]
Hinrichs A (2026). [PMID: 41125144](https://pubmed.ncbi.nlm.nih.gov/41125144/). *Mol Metab*. [Basic Science / Preclinical]
Wu FY (2025). [PMID: 40998191](https://pubmed.ncbi.nlm.nih.gov/40998191/). *Eur J Pharmacol*. [Gene Therapy / Novel Therapeutics]